Nanobiotix annual ebitda margin
2018
2019
2020
2021
2022
2023
2025
Nanobiotix EBITDA Margin Growth & History (NANO)
Nanobiotix's ebitda margin was −31.45% for fiscal 2025.
View full Nanobiotix company overviewNanobiotix annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −31.45% | — |
| 2023 | 2023-12-31 | −84.06% | +862.38 pp |
| 2022 | 2022-12-31 | −946.44% | +980.99 pp |
| 2021 | 2021-12-31 | −1,927.43% | −547.09 pp |
| 2020 | 2020-12-31 | −1,380.33% | +391.09 pp |
| 2019 | 2019-12-31 | −1,771.43% | −924.98 pp |
| 2018 | 2018-12-31 | −846.45% | — |
Nanobiotix ebitda margin trends
Over the last five fiscal years, Nanobiotix's ebitda margin increased from −1,380.33% to −31.45%, a change of +1348.88 percentage points.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nanobiotix source filings ↗Community posts
Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subse ...
